122 related articles for article (PubMed ID: 35701253)
1. A radiation resistance related index for biochemical recurrence and tumor immune environment in prostate cancer patients.
Ke ZB; You Q; Chen JY; Sun JB; Xue YT; Zhuang RB; Zheng QS; Chen YH; Wei Y; Sun XL; Xue XY; Xu N
Comput Biol Med; 2022 Jul; 146():105711. PubMed ID: 35701253
[TBL] [Abstract][Full Text] [Related]
2. A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer.
Ke ZB; You Q; Sun JB; Zhu JM; Li XD; Chen DN; Su L; Zheng QS; Wei Y; Xue XY; Xu N
Front Cell Dev Biol; 2021; 9():774625. PubMed ID: 35071228
[No Abstract] [Full Text] [Related]
3. A Liquid-Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients.
You Q; Chen JY; Wu XH; Xue YT; Sun JB; Wei Y; Zheng QS; Xue XY; Chen DN; Xu N
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982591
[TBL] [Abstract][Full Text] [Related]
4. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer.
Ren C; Wang Q; Wang S; Zhou H; Xu M; Li H; Li Y; Chen X; Liu X
Front Endocrinol (Lausanne); 2023; 14():1148117. PubMed ID: 37033267
[TBL] [Abstract][Full Text] [Related]
6. A Ferroptosis-Related Gene Prognostic Index Associated With Biochemical Recurrence and Radiation Resistance for Patients With Prostate Cancer Undergoing Radical Radiotherapy.
Feng D; Shi X; Xiong Q; Zhang F; Li D; Wei W; Yang L
Front Cell Dev Biol; 2022; 10():803766. PubMed ID: 35223835
[No Abstract] [Full Text] [Related]
7. Comprehensive analysis of the biological functions of endoplasmic reticulum stress in prostate cancer.
Cen S; Jiang D; Lv D; Xu R; Hou J; Yang Z; Wu P; Xiong X; Gao X
Front Endocrinol (Lausanne); 2023; 14():1090277. PubMed ID: 36967783
[TBL] [Abstract][Full Text] [Related]
8. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
9. A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer.
Chen JY; Huang XY; Lin F; You Q; Xue YT; Lin B; Zheng QS; Wei Y; Xue XY; Li XD; Chen DN; Xu N
Genomics; 2023 Sep; 115(5):110691. PubMed ID: 37516327
[TBL] [Abstract][Full Text] [Related]
10. Exploration of gene expression profiles and immune microenvironment between high and low tumor mutation burden groups in prostate cancer.
Luo C; Chen J; Chen L
Int Immunopharmacol; 2020 Sep; 86():106709. PubMed ID: 32593155
[TBL] [Abstract][Full Text] [Related]
11. The Prognosis-Predictive and Immunoregulatory Role of SUMOylation Related Genes: Potential Novel Targets in Prostate Cancer Treatment.
Sun JX; An Y; Xiang JC; Xu JZ; Hu J; Wang SG; Xia QD
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686409
[TBL] [Abstract][Full Text] [Related]
12. A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer.
Hu D; Cao Q; Tong M; Ji C; Li Z; Huang W; Jin Y; Tong G; Wang Y; Li P; Zhang H
BMC Med Genomics; 2022 Feb; 15(1):24. PubMed ID: 35135561
[TBL] [Abstract][Full Text] [Related]
13. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
14. Expression of 5-methylcytosine regulators is highly associated with the clinical phenotypes of prostate cancer and DNMTs expression predicts biochemical recurrence.
Wang L; Ren G; Lin B
Cancer Med; 2021 Aug; 10(16):5681-5695. PubMed ID: 34227253
[TBL] [Abstract][Full Text] [Related]
15. A nomogram concerning immune infiltration and radiosensitivity to predict biochemical recurrence after radical radiation therapy in prostate cancer.
Qiu C; Zhou X; Chen Z; Ren H
J BUON; 2021; 26(4):1612-1622. PubMed ID: 34565026
[TBL] [Abstract][Full Text] [Related]
16. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer.
Liu B; Li X; Li J; Jin H; Jia H; Ge X
Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
18. Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.
Zhang G; Luo Y; Dong W; Zhong W
Comput Math Methods Med; 2022; 2022():8233840. PubMed ID: 35516457
[TBL] [Abstract][Full Text] [Related]
19. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
20. Predicting survival of men with recurrent prostate cancer after radical prostatectomy.
Dell'Oglio P; Suardi N; Boorjian SA; Fossati N; Gandaglia G; Tian Z; Moschini M; Capitanio U; Karakiewicz PI; Montorsi F; Karnes RJ; Briganti A
Eur J Cancer; 2016 Feb; 54():27-34. PubMed ID: 26707594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
